Axon Enterprise vs. Celsius: Comparing Steady Incremental Gains and Historical Volatility in Quarterly Revenue Trends

Axon Enterprise shows steadier momentum versus Celsius, with 30%+ revenue growth in each of the last eight quarters (Axon revenue +66% from Q3 2024 to Q2 2026) while Celsius growth decelerated (+204% over the same period). Axon reported ~5% operating margin for the quarter ended June 30, 2026, versus Celsius at ~9% but amid executive realignment and legal investigations after a recent financial shortfall. The piece suggests investors should watch whether Axon’s revenue gap continues widening or Celsius reaccelerates as it manages internal issues and consumer demand shifts.

Analysis

AXON deserves its premium because the revenue stream is increasingly annuity-like: software attach, replenishment cycles, and public-sector procurement tend to be stickier than consumer beverage demand. That said, at this valuation the equity is no longer being paid for growth alone; it is being paid for sustained margin expansion, so any quarter that shows strong bookings but flat operating leverage can still lead to multiple compression. The near-term catalyst to watch is not headline revenue, but whether the margin bridge starts moving toward high-single-digits over the next 1-3 quarters.

CELH’s issue is less the absolute size of the business than the quality of growth. In beverage, a plateau often forces heavier promotional spend, which can keep reported sales from falling while quietly eroding unit economics; Pepsi’s distribution helps reach, but it can also mask soft sell-through until retailers push back on shelf space. If growth does not reaccelerate within 1-2 quarters, the market will likely re-rate CELH toward slower-growth beverage peers, with MNST the clearest share-grab beneficiary and PEP mostly insulated.

Contrarian take: the consensus may be too linear on both names. AXON can keep compounding without needing explosive top-line acceleration if software mix expands, while CELH could surprise on innovation or international restocking after a period of digestion. The cleaner expression is relative rather than directional: own quality durability, but respect that AXON’s multiple is vulnerable if execution merely stays good instead of improving, and CELH’s short only works if velocity metrics stay weak through the next two reports.

Key Decisions for Investors

• AXON: stay tactically bullish only on pullbacks, using a 3-6 month call spread rather than outright stock. Risk/reward is favorable only if the next 1-2 quarters show margin lift; falsify the thesis if operating margin stays pinned near current levels or if large-order timing slips.
• CELH: initiate or add to a short on any relief rally via put spreads into the next earnings window. This is a 1-3 month trade on reacceleration failure; cover if sequential revenue growth improves materially or channel checks show stronger sell-through.
• Relative value: long PEP / short CELH as the cleaner distribution-vs-brand-execution pair trade. PEP captures the economics of distribution regardless of CELH’s product momentum, while CELH faces the higher risk of promo intensity and shelf pressure if velocity remains soft.
• Watch-list, not a recommendation: MNST as a beneficiary if CELH’s slowdown persists. If CELH continues to lose share but category demand stays intact, MNST is the likely absorber of displaced shelf space over the next 1-2 quarters.
• Avoid chasing AXON after a strong print unless next guidance implies operating leverage acceleration. At ~250x earnings, upside is best captured through optionality; if growth remains consistent but not faster, the stock can de-rate even with good fundamentals.